Skip to main content
. Author manuscript; available in PMC: 2017 May 24.
Published in final edited form as: Circulation. 2016 Apr 27;133(21):1995–2007. doi: 10.1161/CIRCULATIONAHA.115.020259

Table 1.

Baseline Characteristics of the Quality of Life Subset in the PROMISE Trial.

Randomized Treatment Arm
Characteristic Overall
(N= 5985)
Anatomic
(N= 2982)
Functional
(N= 3003)
Mean age – years 60.0 59.8 60.1
Female sex (%) 52.0 51.5 52.5
Racial or ethnic minority (%) 21.7 22.4 21.0
Cardiac risk factor
 Mean body mass index (kg/m2) 29.7 29.6 29.9
 Hypertension (%) 65.9 65.8 66.0
 Diabetes (%) 21.2 21.2 21.2
 Dyslipidemia (%) 67.9 67.3 68.4
 Family history of premature CAD (%) 31.0 32.0 30.1
 Peripheral arterial or cerebrovascular disease (%) 5.9 5.5 6.3
 CAD risk equivalent (%) 25.4 24.9 25.8
 Metabolic syndrome (%) 37.9 37.4 38.4
 Current or past tobacco use (%) 51.5 51.6 51.4
 Sedentary lifestyle (%) 51.4 51.6 51.3
 History of depression (%) 21.1 20.2 22.0
Relevant medication
 Beta blocker (%) 23.5 23.8 23.1
 ACE inhibitor or ARB (%) 42.2 41.7 42.7
 Statin (%) 44.7 44.5 44.8
 Aspirin (%) 42.7 43.1 42.3
Primary presenting symptom
 Chest pain (%) 73.3 74.2 72.5
 Dyspnea on exertion (%) 15.4 14.8 15.9
 Other (%) 11.3 11.0 11.6
Type of angina
 Typical (%) 11.4 11.4 11.4
 Atypical (%) 78.0 77.7 78.2
 Non-cardiac (%) 10.6 10.9 10.4

CAD=coronary artery disease; ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker Race was self-reported on the clinical case report form.